AbbVie Inc. (NYSE:ABBV)

CAPS Rating: 4 out of 5

Results 1 - 20 of 52 : 1 2 3 Next »

Recs

0
Member Avatar derbydog85 (< 20) Submitted: 5/4/2016 11:33:22 PM : Outperform Start Price: $61.41 ABBV Score: +1.80

A stock I can own forever.

Recs

0
Member Avatar EricJohn007 (54.52) Submitted: 4/15/2016 3:21:08 AM : Outperform Start Price: $54.99 ABBV Score: +10.56

High dividend stock with good growth.

Recs

0
Member Avatar MightyMinnow (39.67) Submitted: 3/31/2016 9:17:33 AM : Outperform Start Price: $56.48 ABBV Score: +10.83

sick world

Recs

0
Member Avatar dunloggin (64.67) Submitted: 3/23/2016 2:16:56 PM : Outperform Start Price: $56.17 ABBV Score: +10.48

Pretty safe dividend, 4% yield.

Recs

0
Member Avatar DCUDFlyer (31.91) Submitted: 3/8/2016 10:07:41 AM : Outperform Start Price: $55.64 ABBV Score: +9.09

In at 57.99 - growth at a reasonable price, solid yield.

Recs

0
Member Avatar reddingrunner (90.97) Submitted: 1/19/2016 1:25:02 PM : Outperform Start Price: $55.06 ABBV Score: +4.15

Sabrient Baker's Dozen 2016

Recs

0
Member Avatar 1russianguy (38.19) Submitted: 1/19/2016 12:36:52 PM : Outperform Start Price: $55.42 ABBV Score: +3.48

SBD2016

Recs

0
Member Avatar jjcylk (67.81) Submitted: 1/14/2016 12:15:44 PM : Outperform Start Price: $51.87 ABBV Score: +12.86

I need to watch this closer. I am not sure which to hold this or ABT?

Recs

0
Member Avatar steelers50 (25.50) Submitted: 12/24/2015 10:23:35 AM : Outperform Start Price: $57.26 ABBV Score: +9.38

Growth and Fundamentals

Recs

0
Member Avatar alansfinance (43.72) Submitted: 12/6/2015 3:13:19 PM : Outperform Start Price: $55.50 ABBV Score: +14.10

Stock protected by 4% yield. Gambling that DEM's lose.

Recs

0
Member Avatar northjm (< 20) Submitted: 9/22/2015 2:09:34 PM : Outperform Start Price: $55.53 ABBV Score: +6.10

Good stock

Recs

0
Member Avatar racoveanul (74.58) Submitted: 6/28/2015 5:15:24 AM : Outperform Start Price: $66.79 ABBV Score: -5.19

ABBVIE INC, ticker ABBV, has a TTM ROE calculated by Zacks of 177,11%. It's one of my LONG picks.

Recs

1
Member Avatar DrGoldin (99.66) Submitted: 5/16/2015 12:22:36 AM : Outperform Start Price: $61.69 ABBV Score: +2.57

This and BMY are probably the best old-school pharma names right now, but ABBV is a lot cheaper. We're looking at easily 15% annual growth over the next several years (fueled by Humira, Viekira, and of course the shrewd acquisition of Pharmacyclics), and you're only paying 15-16x 2015 earnings for it. So not quite as much growth as Bristol Myers, but not nearly the price, either. Growth at a reasonable price, baby. And I'm not even considering the nice 3% dividend. I'm in at 64.68; I wish I had had the idea ten points ago, but I'm still very comfortable with this entry point.

The only thing I don't like about AbbVie is the dumb name.

Recs

0
Member Avatar Kimer62 (25.02) Submitted: 5/9/2015 8:43:24 AM : Outperform Start Price: $62.89 ABBV Score: +1.97

conservative value play

Recs

0
Member Avatar CellBlock9 (91.33) Submitted: 4/26/2015 11:02:55 AM : Outperform Start Price: $63.66 ABBV Score: +1.39

mgk, 66.07

Recs

0
Member Avatar PuckFan26 (< 20) Submitted: 4/16/2015 9:27:43 PM : Outperform Start Price: $60.20 ABBV Score: +5.50

investment in pharmacyclics will end up paying off in the end and turn into profit. One of the leaders in pharmacyclics is known to make great products and make successful companies

Recs

0
Member Avatar ZenRiDr (68.61) Submitted: 3/2/2015 8:21:06 PM : Outperform Start Price: $57.72 ABBV Score: +11.08

Will have about 15% share if HCV market. Humira.

Recs

0
Member Avatar Dreadnought (53.53) Submitted: 2/28/2015 12:01:12 AM : Outperform Start Price: $57.67 ABBV Score: +10.86

I am going to guess that this company supports Richard Branson and Jeb Bush at the poles. Then again, I might just be thinking about GILD.

Recs

1
Member Avatar bdbcalm (< 20) Submitted: 2/15/2015 4:54:27 PM : Outperform Start Price: $54.55 ABBV Score: +16.91

Sold off due to patent cliff concerns and Hep C drug discounts. I believe this is an overreaction and the stock will recover. There is more in the pipeline than the P/E - 13 - would imply.

Results 1 - 20 of 52 : 1 2 3 Next »

Featured Broker Partners